GUIDE Sosiete

FDA Clinical Decision Support Software Guidance

FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply.

  • 3 simili jàng
  • Dañu mujjee yeesal
Ci xët wii3 simili jàng
  1. Résumé
  2. Plongeur bu xóot
  3. njeextalu pexe
  4. The Future of FDA Clinical Decision Support Software Guidance
  5. Doxal ci àdduna dëgg
  6. Risk yi ak balustrade yi
  7. Roadmap ngir samp gi
  8. Weyal di banneexu
  9. Laaj yi ñuy faral di laaj

Résumé

The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.

Plongeur bu xóot

Clinical decision support software provides information or recommendations to support healthcare decisions. FDA’s guidance explains how the agency assesses software functions under the applicable statutory criteria. Some functions may be excluded from the device definition when they meet specific conditions, including that a health professional can independently review the basis for recommendations. Other functions, including certain patient-specific analyses or device functions, may remain subject to oversight. The assessment is about what a particular software function does, its intended user, and how the output is used. A product can contain multiple functions with different regulatory status. A tool that presents evidence for a clinician to review is not automatically treated the same as software that directs diagnosis or treatment. FDA guidance also notes that functions intended for patients or caregivers may be assessed differently from clinician-facing support. Manufacturers should define each function and provide information that supports independent review where relevant. Clinicians should understand what inputs and evidence support a recommendation, the intended population, and limitations. A generated explanation is not itself proof of the underlying basis. Check current FDA guidance and product labeling for the specific function. This guide summarizes concepts and does not determine regulatory status for a product. Preserve examples of intended use and evidence that support the analysis, and revisit it when users, claims, or outputs change. Keep patient-facing and clinician-facing functions distinct in requirements and documentation.

njeextalu pexe

Risk ak kaaraange

Gaañ-gaañu IA yu mag yi ak yu bës bu nekk yépp a ngi aju ci ki xam risk yi ak ki mëna def dara.

dogal yu gëna leer

Liggéeyukaay ak xam-xam bu ñépp bokk mooy wane ndax politiku kaaraange bu dëgër mën na am ci wàllu politik.

Dagg ci hype

Faram-fàcce yu leer dañuy wàññi li ñuy jàpp ci hype, PR lab, ak tiyaatar bu leerul.

The Future of FDA Clinical Decision Support Software Guidance

Decision-support products increasingly use machine learning and generative models, creating new questions about explainability and how clinicians review evidence. FDA guidance is updated as laws and technology change. Developers should monitor current agency materials and preserve a function-level analysis. Care teams need training to interpret outputs and should retain clinical judgment even when a tool is authorized. Developers should design interfaces that make the evidence and limitations easy to inspect, not merely generate a plausible explanation. Monitor outcomes and user feedback.

Doxal ci àdduna dëgg

A clinician reviews sources and rationale behind a recommendation before acting.

A software team separates administrative reminders from patient-specific treatment recommendations.

A hospital confirms whether a function is intended for health professionals or patients.

A developer maps the product’s intended use to the criteria in current FDA guidance.

Risk yi ak balustrade yi

  • Jàppale risku nekk gi ni siyaas fiksioŋ fekk kàttan gi dafay yokk.

  • Jaxasoo kaaraange produit surface ak jubluwaay ci suufu autonomie bu kawe.

  • Bàyyi nit ñi xamul làkku Àngle ak ñi xamul làkku Angale, ñu am balluwaay yu baaxul.

Roadmap ngir samp gi

  1. Tàqale loraange yi ci produit bi, jëfandikoo bu baaxul, ak risku ñàkka mëna yor / ñàkka méngoo.

  2. Laajteel ban firnde mooy soppi sa xalaat ci kalendriye yi ak tar gi.

  3. Danga taamu balluwaay yu njëkk yi ak jàngat yu fëgër yi moo gën waxtaanu njaay mi.

  4. Xaarandil benn yoonu jëf: liggéey, politik, xaalis, wala xam-xam — du xam-xam kese.

Weyal di banneexu

Free newsletter

Get the daily AI briefing

Three verified AI stories every weekday morning, written in plain English. Free forever, no ads.

One email each weekday. Unsubscribe in one click. We never sell or share your address.

Test yourself

Take the FDA Clinical Decision Support Software Guidance quiz

Instant feedback on every answer, and a shareable certificate with a verifiable ID once you pass a course.

Tambalil quiz

Support free AI education. AI Understanding is a 501(c)(3) nonprofit — no ads, no paywall, ever. Make a donation

Laaj yi ñuy faral di laaj

What is FDA Clinical Decision Support Software Guidance?

FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply. The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.

What does FDA evaluate in clinical decision-support software?

Regulatory analysis depends on the function and how it is used.

Why analyze a product function by function?

Regulatory assessment is not necessarily product-wide and uniform.

What should developers document for a function?

Function-specific documentation supports assessment and use.

What should clinicians do with a CDS recommendation?

CDS supports decisions and does not replace professional review.